Trial abstract · §3
CAGRI-SEMA-PH2-T2D — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in glycated haemoglobin from baseline to week 32 | Weight change of approximately −15.6 % in the combination arm; the small sample is the reason the Institute treats the phase 2 estimate as hypothesis-generating | Low |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for CagriSema (cagrilintide with semaglutide) from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | — | — | Combination gastrointestinal burden is broadly the sum of the component profiles rather than additive beyond it |
| Vomiting | — | — | Reported at higher incidence than semaglutide monotherapy in cross-trial comparison, which the Institute notes is not a randomised comparison |
| Discontinuation for adverse events | 6.0 | 3.0 | REDEFINE 1 (approximate) |
Compound Evidence Institute · CEI-TR-0052/3 · https://compoundevidence.com/trials/cagri-sema-ph2-t2d/results/ · retrieved 30 July 2026